Abstract
Design: Recombinant human TSH-stimulated thyroglobulin (Tg) levels (rhTSH-Tg) are sufficient for early follow-up of low-risk differentiated thyroid cancer (DTC) patients after thyroidectomy and radioiodine (131I) remnant ablation (RAI). Serum Tg levels at the time of remnant ablation (ablation-Tg) is thought to be related with rhTSH-Tg and may be predictive of recurrent disease. During long-term follow-up, Tg levels on levo-T4 (L-T4) suppressive treatment (suppressive-Tg) is sufficiently sensitive to avoid further evaluations in patients with undetectable rhTSH-Tg. The aim of our study was to verify whether, in a subgroup of low-risk DTC patients, the association of low ablation-Tg levels (<10 μg/l) with undetectable suppressive-Tg concentrations has a sufficient negative predictive value (NPV) for recurrence of disease, leading to avoid rhTSH testing. Methods: We enrolled 169 low-risk DTC patients treated by thyroidectomy + RAI and undetectable suppressive-Tg at 12-month follow-up. In all patients, we retrospectively evaluated ablation-Tg and rhTSH-Tg. For all patients, 2-yr follow-up was available. Results: Based on rhTSH-Tg>2 μg/l, relapsing disease was histologically proven in 2 patients. rhTSH-Tg levels between 0.6–2.0 μg/l, with no evidence of disease, was observed in 10 patients (6%). One hundred and fifty-seven patients showed undetectable rhTSH-Tg. The NPV of undetectable suppressive-Tg was 92.8%. The ablation-Tg level was <10 μg/l in 140 patients. In this group, the NPV of undetectable suppressive-Tg was 100%. Conclusion: Our data indicate that undetectable suppressive-Tg value, combined with ablation-Tg levels <10 μg/l, may avoid a significant number of high-cost rhTSH-Tg test.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Schlumberger M. Papillary and follicular thyroid carcinoma. New Engl J Med 1998, 338: 297–306.
Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86: 1447–63.
Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998, 138: 249–52.
Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999, 9: 435–41.
Cooper DS, Doherty GM, Haugen BR, et al; The American Thyroid Association Guidelines. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16: 109–42.
Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 1433–41.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154: 787–803.
Rosário PW, Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low risk patients with thyroid carcinoma and undetectable Tg on thyroxine and negative neck ultrasound. Clin Endocrinol (Oxf) 2005, 62: 121–5.
Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay during thyroxine treatment in low-risk differetiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006, 44: 648–52.
Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008, 93: 76–81.
Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999, 26: 1448–52.
Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004, 45: 988–94.
Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005, 43: 843–7.
Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005, 90: 1440–5.
Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002, 94: 2511–6.
Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recom-binant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002, 87: 1490–8.
Robbins RJ, Chon JT, Fleisher M, Larson S, Tuttle RM. Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to-monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002, 87: 3242–7.
Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999, 84: 3877–85.
David A, Blotta A, Bondanelli M, et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001, 42: 1470–5.
Vitale G, Lupoli GA, Ciccarelli A, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 2002, 56: 247–52.
Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002, 12: 37–43.
Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001, 86: 5686–90.
Wartofsky L; rhTSH-Stimulated Thyroglobulin Study Group. Management of low-risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-stimulated Thyroglobulin Study Group. Thyroid 2002, 12: 583–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Piccardo, A., Arecco, F., Morbelli, S. et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Invest 33, 83–87 (2010). https://doi.org/10.1007/BF03346558
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346558